Your browser is no longer supported. Please, upgrade your browser.
Settings
PRLD [NASD]
Prelude Therapeutics Incorporated
Index- P/E- EPS (ttm)- Insider Own0.40% Shs Outstand45.12M Perf Week-7.65%
Market Cap1.53B Forward P/E- EPS next Y-3.10 Insider Trans-49.36% Shs Float43.59M Perf Month15.23%
Income- PEG- EPS next Q-0.49 Inst Own81.50% Short Float8.15% Perf Quarter-19.70%
Sales- P/S- EPS this Y29.30% Inst Trans0.04% Short Ratio16.39 Perf Half Y-57.04%
Book/sh7.90 P/B4.05 EPS next Y-48.30% ROA- Target Price- Perf Year-
Cash/sh7.57 P/C4.23 EPS next 5Y30.10% ROE- 52W Range23.69 - 95.38 Perf YTD-55.28%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-66.45% Beta-
Dividend %- Quick Ratio29.40 Sales past 5Y- Gross Margin- 52W Low35.06% ATR2.57
Employees68 Current Ratio29.40 Sales Q/Q- Oper. Margin- RSI (14)52.19 Volatility7.94% 9.68%
OptionableNo Debt/Eq0.00 EPS Q/Q79.90% Profit Margin- Rel Volume0.58 Prev Close31.73
ShortableYes LT Debt/Eq0.00 EarningsMay 11 BMO Payout- Avg Volume216.75K Price32.00
Recom2.60 SMA206.41% SMA502.14% SMA200-34.29% Volume125,019 Change0.85%
Jul-27-21Upgrade BofA Securities Neutral → Buy $60
Apr-26-21Initiated H.C. Wainwright Buy $62
Mar-09-21Initiated Barclays Overweight $80
Nov-20-20Downgrade BofA Securities Buy → Neutral $40 → $60
Oct-20-20Initiated Morgan Stanley Equal-Weight $34
Oct-20-20Initiated Goldman Neutral $37
Oct-20-20Initiated BofA Securities Buy $40
Jul-19-21 07:00AM  
May-13-21 07:15AM  
May-11-21 07:30AM  
May-05-21 07:00AM  
Apr-20-21 07:42AM  
Mar-16-21 08:00AM  
Mar-03-21 07:00AM  
Jan-11-21 06:20PM  
Jan-07-21 12:12AM  
Jan-04-21 04:16PM  
Dec-25-20 04:01AM  
Dec-15-20 11:42PM  
Nov-10-20 07:30AM  
Oct-02-20 08:00PM  
Oct-01-20 11:57AM  
Sep-30-20 07:00AM  
Sep-29-20 04:05PM  
Sep-25-20 02:31PM  
08:47AM  
Sep-24-20 08:50PM  
10:52AM  
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; and PRT-K4 that is in preclinical stage for solid tumors. Prelude Therapeutics Incorporated was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Scherle PeggyChief Scientific OfficerJul 27Option Exercise1.4320,00028,600192,920Jul 29 07:27 PM
Scherle PeggyChief Scientific OfficerJul 27Sale35.4720,000709,380172,920Jul 29 07:27 PM
Mauro David JChief Medical OfficerJul 06Option Exercise1.8915,00028,35015,000Jul 08 05:41 PM
Mauro David JChief Medical OfficerJul 06Sale27.4715,000412,1070Jul 08 05:41 PM
Mauro David JChief Medical OfficerJun 07Option Exercise1.8915,00028,35015,000Jun 09 06:24 PM
Mauro David JChief Medical OfficerJun 07Sale32.4415,000486,6220Jun 09 06:24 PM
Piper BrianChief Financial OfficerMay 25Option Exercise1.898,33315,7498,333May 27 05:03 PM
Piper BrianChief Financial OfficerMay 25Sale34.278,333285,5370May 27 05:03 PM
Scherle PeggyChief Scientific OfficerMay 07Option Exercise1.4310,00014,300182,920May 11 06:46 PM
Scherle PeggyChief Scientific OfficerMay 07Sale40.8210,000408,192172,920May 11 06:46 PM
Mauro David JChief Medical OfficerMay 05Option Exercise1.8915,00028,35015,000May 10 04:37 PM
Mauro David JChief Medical OfficerMay 05Sale40.1415,000602,0920May 10 04:37 PM
Morosini DeborahEVP, Chief of Clinical AffairsApr 29Option Exercise1.893,2236,0913,667Apr 30 06:22 PM
Pierce ChristopherEVP and Chief of Business OperApr 29Option Exercise1.893,2956,2287,045Apr 30 06:24 PM
Pierce ChristopherEVP and Chief of Business OperApr 29Sale40.293,295132,7653,750Apr 30 06:24 PM
Morosini DeborahEVP, Chief of Clinical AffairsApr 29Sale40.293,223129,853444Apr 30 06:22 PM
Mauro David JChief Medical OfficerApr 27Option Exercise1.8925,00047,25025,000Apr 29 05:14 PM
Mauro David JChief Medical OfficerApr 27Sale35.3925,000884,8480Apr 29 05:14 PM
Mauro David JChief Medical OfficerApr 19Option Exercise1.8925,00047,25025,000Apr 21 07:56 PM
Mauro David JChief Medical OfficerApr 19Sale30.8925,000772,3490Apr 21 07:56 PM
Mauro David JChief Medical OfficerApr 08Option Exercise1.899,61718,1769,617Apr 15 07:09 PM
Morosini DeborahEVP, Chief of Clinical AffairsApr 08Option Exercise1.89100189544Apr 15 07:11 PM
Mauro David JChief Medical OfficerApr 08Sale38.359,617368,8520Apr 15 07:09 PM
Scherle PeggyChief Scientific OfficerApr 08Sale38.344,630177,504172,920Apr 15 07:14 PM
Pierce ChristopherEVP and Chief of Business OperApr 08Sale40.002008,0003,750Apr 15 07:12 PM
Morosini DeborahEVP, Chief of Clinical AffairsApr 08Sale40.001004,000444Apr 15 07:11 PM
Mauro David JChief Medical OfficerApr 07Option Exercise1.8915,38329,07415,383Apr 09 05:50 PM
Morosini DeborahEVP, Chief of Clinical AffairsApr 07Option Exercise1.891,0001,8901,444Apr 09 05:52 PM
Mauro David JChief Medical OfficerApr 07Sale39.3315,383605,0230Apr 09 05:50 PM
Scherle PeggyChief Scientific OfficerApr 07Sale39.3115,370604,144172,920Apr 09 05:55 PM
Pierce ChristopherEVP and Chief of Business OperApr 07Sale40.0882833,1883,750Apr 09 05:53 PM
Morosini DeborahEVP, Chief of Clinical AffairsApr 07Sale40.041,00040,043444Apr 09 05:52 PM
BAKER BROS. ADVISORS LPDirectorJan 27Option Exercise12.8510,376133,3329,252,951Jan 29 07:04 PM